Richard William Price

Richard William Price's AcademicInfluence.com Rankings

Psychology

#2591

World Rank

#2994

Historical Rank

Neuropsychology

#64

World Rank

#67

Historical Rank

psychology Degrees

Richard William Price

Philosophy

#5832

World Rank

#8742

Historical Rank

Logic

#3040

World Rank

#4137

Historical Rank

philosophy Degrees

Download Badge

Psychology
Philosophy

Richard William Price's Degrees

PhD Psychology University of California, San Diego
Doctorate Medicine University of California, San Francisco

Why Is Richard William Price Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard William Price's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Updated research nosology for HIV-associated neurocognitive disorders (2007) (2343)
The AIDS dementia complex: I. Clinical features (1986) (1634)
The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. (1988) (1295)
The AIDS dementia complex: II. Neuropathology (1986) (1277)
The AIDS dementia complex. (1988) (1267)
HTLV-III infection in brains of children and adults with AIDS encephalopathy. (1985) (857)
Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection (1991) (773)
Quinolinic acid in cerebrospinal fluid and serum in HIV‐1 Infection: Relationship to clinical and neurological status (1991) (553)
Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. (1985) (549)
Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: Clinical and neuropathological findings in 27 patients (1986) (474)
Neuropathology of Acquired Immunodeficiency Syndrome (AIDS): An Autopsy Review (1986) (456)
Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes (1991) (387)
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study (2015) (353)
The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. (1987) (351)
HIV‐Associated Disease of the Nervous System: Review of Nomenclature and Proposal for Neuropathology‐Based Terminology (1991) (335)
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo (1992) (293)
HIV antigen in the brains of patients with the AIDS dementia complex (1987) (291)
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. (2010) (277)
Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient (2013) (275)
Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial (1993) (274)
AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlations (1995) (270)
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 (2020) (256)
The metabolic pathology of the AIDS dementia complex (1987) (239)
HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types (2011) (231)
Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load (2012) (226)
Neuropsychological characterization of the AIDS dementia complex: a preliminary report. (1988) (225)
HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. (1984) (212)
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? (2011) (207)
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection (2010) (205)
Progressive multifocal leukoencephalopathy in HIV-1 infection. (2009) (190)
Latent Ganglionic Infection with Herpes Simplex Virus Types 1 and 2: Viral Reactivation in vivo after Neurectomy (1974) (180)
Thrombotic cerebral vasculopathy associated with herpes zoster (1986) (176)
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study (2017) (171)
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. (2007) (169)
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation (1992) (165)
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. (2006) (159)
Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment (2005) (158)
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection (1990) (158)
Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection (2015) (156)
Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection (2009) (152)
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. (2013) (149)
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. (1999) (143)
Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. (1999) (139)
Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia (2009) (138)
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. (2002) (137)
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection (2009) (137)
Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients (2014) (136)
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. (2011) (135)
Large Differences in Small RNA Composition Between Human Biofluids (2018) (132)
Antiretroviral therapy and central nervous system HIV type 1 infection. (2008) (132)
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and β2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients (1992) (130)
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation (2014) (129)
CSF neurofilament protein (NFL) — a marker of active HIV-related neurodegeneration (2007) (121)
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course (2009) (112)
The aids dementia complex: Some current questions (1988) (111)
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. (2007) (111)
Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy (2008) (111)
HIV‐Related Neuropathology, 1985 to 1999: Rising Prevalence of HIV Encephalopathy in the Era of Highly Active Antiretroviral Therapy (2002) (110)
Human immunodeficiency virus and the central nervous system. (1992) (108)
Neurological complications of HIV infection (1996) (105)
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. (2006) (104)
Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization. (1975) (103)
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection (2009) (101)
Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls (2017) (98)
Cerebrospinal fluid (β2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment (1992) (98)
HIV, AIDS, And the Brain (1994) (97)
Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy (2015) (92)
Early HIV‐1 infection and the AIDS dementia complex (1990) (90)
Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection (2014) (90)
Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug. (1982) (89)
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections (2013) (89)
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. (2009) (88)
Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment (2016) (87)
Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. (1988) (87)
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. (2007) (87)
Multifocal varicella‐zoster virus leukoencephalitis temporally remote from herpes zoster (1981) (85)
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection (2007) (85)
Biomarkers of HIV-1 CNS infection and injury (2007) (83)
Cerebrospinal fluid interferon-γ-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection (2005) (82)
Latent infection of the peripheral ANS with herpes simplex virus (1975) (82)
British Identities before Nationalism: Ethnicity and Nationhood in the Atlantic World, 1600-1800@@@British Society, 1680-1880: Dynamism, Containment and Change (1999) (78)
HTLV‐I—associated myelopathy/tropical spastic paraparesis in the United States (1991) (74)
Measuring the “viral load” in cerebrospinal fluid in human immunodeficiency virus infection: Window into brain infection? (1997) (74)
Human immunodeficiency virus (HIV) infection and the nervous system (1989) (73)
Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV. (2018) (72)
Resistance of peripheral autonomic neurons to in vivo productive infection by herpes simplex virus mutants deficient in thymidine kinase activity (1981) (72)
Antiretroviral drug treatment of CNS HIV-1 infection. (2012) (72)
Neurological syndromes complicating AIDS. (1985) (71)
AIDS Dementia Complex and HIV‐1 Infection: A View From the Clinic (1991) (70)
Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection (2014) (69)
Cerebrospinal fluid ß2 microglobulin in patients infected with human immunodeficiency virus (1989) (69)
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. (2011) (68)
Reactivation of latent herpes simplex virus infection of the autonomic nervous system by postganglionic neurectomy (1978) (67)
Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. (2004) (67)
Dissociation of AIDS‐related vacuolar myelopathy and productive HIV‐1 infection of the spinal cord (1989) (66)
Evaluation of the AIDS dementia complex in clinical trials. (1990) (65)
Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2. (1977) (65)
Is It Time to Rethink How Neuropsychological Tests Are Used to Diagnose Mild Forms of HIV-Associated Neurocognitive Disorders? Impact of False-Positive Rates on Prevalence and Power (2013) (64)
Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection (2008) (63)
Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment (2005) (61)
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy (2013) (61)
HTLV‐I‐associated myelopathy associated with blood transfusion in the United States (1991) (60)
Timed Gait Test: Normative Data for the Assessment of the AIDS Dementia Complex (2006) (60)
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms (2020) (59)
Progressive multifocal leukoencephalopathy: A burnt‐out case (1983) (59)
Cerebral white matter integrity during primary HIV infection (2015) (58)
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. (2005) (58)
Cerebrospinal fluid response to structured treatment interruption after virological failure (2001) (58)
Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects (2013) (57)
Undetectable Cerebrospinal Fluid HIV RNA and β-2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients (2005) (56)
A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. (2002) (55)
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. (2005) (55)
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. (2012) (55)
Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection (2018) (54)
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection (2005) (54)
HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir (2001) (54)
Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial (2007) (53)
CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. (2004) (53)
Route of infection, systemic host resistance, and integrity of ganglionic axons influence acute and latent herpes simplex virus infection of the superior cervical ganglion (1979) (52)
Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers (2007) (50)
Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials (2008) (50)
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. (2014) (49)
Understanding the AIDS dementia complex (ADC). The challenge of HIV and its effects on the central nervous system. (1994) (48)
Phenotypic Correlates of HIV-1 Macrophage Tropism (2015) (47)
Microglia in the giant cell encephalitis of acquired immune deficiency syndrome: proliferation, infection and fusion (2004) (46)
Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection (2013) (45)
HIV-1 RNA Detected in the CNS after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. (2019) (45)
Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy (2017) (45)
Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection (2014) (45)
The two faces of HIV infection of cerebrospinal fluid. (2000) (44)
The urokinase receptor is overexpressed in the AIDs dementia complex and other neurological manifestations (2004) (44)
AIDS dementia complex and primary HIV brain infection (1988) (44)
Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials (2010) (44)
CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection (2018) (43)
Acid-base balance of cisternal and lumbar cerebrospinal fluid in hospital patients. (1973) (43)
Progressive multifocal leukoencephalopathy (PML) (1980) (42)
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings (2011) (41)
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. (1992) (41)
Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA (2016) (39)
Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV (2016) (39)
The management of the neurological complications of HIV infection and AIDS. (1988) (35)
The AIDS dementia complex and HIV-1 brain infection: a pathogenetic model of virus-immune interaction. (1990) (35)
Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection (2014) (34)
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease (2004) (34)
Evolving Character of Chronic Central Nervous System HIV Infection (2014) (33)
Putamen volume and its clinical and neurological correlates in primary HIV infection (2016) (32)
Failure of atorvastatin to modulate CSF HIV-1 infection (2008) (32)
Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin (2008) (31)
Peripheral Neuropathy in Primary HIV Infection Associates With Systemic and Central Nervous System Immune Activation (2014) (31)
T-Cell Activation and Memory Phenotypes in Cerebrospinal Fluid During HIV Infection (2005) (30)
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity (2012) (29)
Lessons Learned Developing a Diagnostic Tool for HIV-Associated Dementia Feasible to Implement in Resource-Limited Settings: Pilot Testing in Kenya (2012) (28)
Broad screening for human herpesviridae DNA in multiple sclerosis cerebrospinal fluid and serum. (2009) (28)
Confirmation of HTLV-III virus in cornea. (1986) (28)
Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. (2007) (28)
Dementia Complicating AIDS 7 (1986) (27)
Longitudinal Characterization of Depression and Mood States Beginning in Primary HIV Infection (2014) (27)
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? (2018) (26)
Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS. (2019) (26)
Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals. (2017) (26)
Viral infections of the autonomic nervous system and its target organs: pathogenetic mechanisms. (1977) (25)
Pursuit eye movement dysfunction in HIV-1 seropositive individuals. (1991) (24)
Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals (2015) (24)
Management of the neurologic complications of HIV infection and AIDS. (1988) (23)
Another retroviral disease of the nervous system: chronic progressive myelopathy due to HTLV-1. (1988) (23)
Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation (2010) (23)
Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers (2013) (22)
Utility of Quantitative Sensory Testing and Screening Tools in Identifying HIV-Associated Peripheral Neuropathy in Western Kenya: Pilot Testing (2010) (22)
Infections in AIDS and in other immunosuppressed patients (1987) (22)
6-Hydroxydopamine potentiates acute herpes simplex virus infection of the superior cervical ganglion in mice. (1979) (21)
Moral norms in world politics 1 (1997) (21)
3.7 How HIV leads to neurological disease (1996) (19)
The cellular basis of central nervous system HIV-1 infection and the AIDS dementia complex: introduction. (1996) (19)
Major Coexisting Human Immunodeficiency Virus Type 1 env Gene Subpopulations in the Peripheral Blood Are Produced by Cells with Similar Turnover Rates and Show Little Evidence of Genetic Compartmentalization (2009) (19)
Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. (1988) (19)
Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system (2011) (19)
An overview of the clinical and biological features of the AIDS dementia complex. (2005) (19)
Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy (2005) (18)
Management of AIDS dementia complex and HIV-1 infection of the nervous system. (1995) (18)
Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression (2021) (17)
Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals (2018) (17)
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study (2011) (17)
No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts (2018) (17)
Infection of the Central Nervous System by Human Immunodeficiency Virus Role of the Immune System in Pathogenesis a (1988) (16)
Prospects for the use of radiolabeled antiviral drugs in the diagnosis of herpes simplex encephalitis. (1983) (16)
An Approach for Incorporating Information on Chemical Availability in Soils into Risk Assessment and Risk-Based Decision Making, Prepared by: The New England Environmentally Acceptable Endpoints Workgroup (2000) (16)
Experience with a cross‐study endpoint review committee for AIDS clinical trials (1998) (16)
Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China (2017) (15)
Training needs and evaluation of a neuro-HIV training module for non-physician healthcare workers in Western Kenya (2011) (15)
Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. (1989) (15)
Interferon protects neurons in culture infected with vesicular stomatitis and herpes simplex viruses (1982) (14)
HIV-Producing T Cells in Cerebrospinal Fluid (2004) (14)
Undetectable tumor necrosis factor‐alpha in a spinal fluid from HIV‐1–infected patients (1992) (13)
The challenge of HIV and its effects on the central nervous system (1992) (13)
AIDS encephalopathy. (1986) (13)
Chemokine receptors, neural progenitor cells, and the AIDS dementia complex. (2004) (12)
Preservation of catecholamine uptake and release in herpes simplex virus type 1-infected PC12 cells. (1983) (12)
Screening for HIV‐associated peripheral neuropathy in resource‐limited settings (2013) (12)
Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence. (2019) (11)
No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau) (2017) (11)
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect (2013) (11)
Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis (2021) (11)
Neuropathy complicating diffuse infiltrative lymphocytosis (1998) (11)
Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. (2019) (11)
AIDS‐related vacuolar myelopathy is not associated with coinfection by human T‐lymphotropic virus Type I (1989) (10)
Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. (2016) (10)
Human T-lymphotropic virus type I-associated myelopathy in patients with the acquired immunodeficiency syndrome. (1992) (10)
What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? (2019) (10)
The AIDS dementia complex: Current status (1987) (10)
Increased Neopterin Levels in Brains of Patients with Human Immunodeficiency Virus Type 1 Infection (1992) (10)
Central nervous system HIV-1 infection. (2014) (10)
Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection (2015) (9)
Neurobiology of human herpesvirus infections. (1986) (9)
Herpes simplex virus latency: adaptation to the peripheral nervous system. I. (1985) (9)
Herpes simplex virus latency: adaptation to the peripheral nervous system. II. (1985) (9)
Tyrosine hydroxylase activity in the superior cervical ganglion during herpes simplex virus infection: Correlation with viral titers and viral antigen (1981) (8)
Myelitis and toxic, inflammatory, and infectious disorders. (1993) (8)
Brain MRI Features of CSF Human Immunodeficiency Virus Escape (2018) (8)
Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance (2020) (8)
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate (2019) (8)
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders (2019) (8)
Stable neurological function in subjects treated with 2'3'-dideoxyinosine. (1997) (7)
DESIGN STUDY OF GRAVITY-INDEPENDENT PHOTOSYNTHETIC GAS EXCHANGER, (1963) (6)
Herpes simplex virus infection of isolated autonomic neurons in culture: Viral replication and spread in a neuronal network (2005) (6)
Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study (2021) (6)
AIDS dementia complex: a complex, slow virus "model" of acquired genetic neurodegenerative disease. (1996) (6)
Central and Peripheral Nervous System Complications of AIDS (1986) (6)
Neurological complications of HIV infection and AIDS: current and future perspectives. (2005) (5)
Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection (2021) (5)
Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140] (2016) (5)
Replication of thymidine kinase deficient herpes simplex virus type 1 in neuronal cell culture: Infection of the PC 12 cell (2005) (5)
Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1 (2020) (5)
OTK18 Levels in Plasma and Cerebrospinal Fluid Correlate with Viral Load and CD8 T-cells in Normal and AIDS Patients (2008) (5)
AIDS Dementia Complex (1988) (4)
Neuropsychological and psychosocial sequelae of AIDS. (1987) (4)
Dementia associated with AIDS. (1988) (4)
Cerebrospinal fluid and plasma lipopolysaccharide (LPS) levels in HIV-1 infection and associations with inflammation, blood-brain barrier permeability and neuronal injury. (2020) (3)
3rd International Congress on Neurology and Epidemiology. Abu Dhabi, UAE, November 21–23, 2013: Abstracts (2013) (3)
AIDS dementia complex and HIV-1 brain infection: a pathogenetic framework for treatment and evaluation. (1995) (3)
Pathogenetic implications of neuropathological findings in the AIDS dementia complex. (1988) (3)
Article Commentary: Targeting Chronic Central Nervous System HIV Infection (2012) (3)
Pilot Study of Didanosine in Patients with HIV Dementia. (1997) (3)
Screening for the AIDS dementia complex. (2002) (3)
Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment (2019) (3)
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy (2013) (3)
Kaposi's sarcoma and central nervous system disease: a real association or an artifact of the control group? Terry Beirn Community Programs for Clinical Research on AIDS. (2000) (3)
HUlVlAN IMMUNODEFICIENCY VIRlJS AND THE CENTRAL NER'VOUS SYSTEM (1992) (3)
NEUROPATHOLOGY OF LAV/HTLV-III ENCEPHALITIS (1986) (2)
Terrorism and Warfare (Chemical, Biological, and Radioactive and Nuclear) (2009) (2)
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity (2012) (2)
Abstract 16. Subacute encephalopathy of AIDS: clinical, pathological and etiological considerations (1985) (2)
Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation (2022) (2)
Relationship between neuropsychological performance, and immune parameters in HIV-1 infected patients with and without AIDS dementia complex (1999) (2)
Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection (2016) (1)
Global Mindset, Networks and Trader Performance: A Study of the Global Grain and Oilseed Sector (2015) (1)
Molecular biology of HIV-1 in AIDS dementia complex (1992) (1)
Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection (2014) (1)
Perspective on HIV CNS Infections (2011) (1)
HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells (2023) (1)
Neuroimaging Findings in HIV-Infected Patients at San Francisco General Hospital, 1997-2012 (P06.181) (2013) (1)
TYROSINE HYDROXYLASE ACTIVITY IN THE MOUSE SUPERIOR CERVICAL GANGLION INFECTED WITH HERPES SIMPLEX VIRUS (1979) (1)
Reply (1987) (0)
complementation.for limited defectiveness and human immunodeficiency virus type 1 in vivo: organization, and biological properties of Complete nucleotide sequence, genome (2013) (0)
The Risk of Large-Artery Atherosclerotic Stroke is Proportionally Greater than Cardioembolic Stroke in HIV-Infected Individuals Compared to HIV-Uninfected Controls (I10-1.003) (2014) (0)
Editorial comment: déjà vu--neurologic complications of HIV infection in the expanding epidemic. (2005) (0)
Cerebrospinal fluid markers in the management of central nervous system HIV infection and the AIDS dementia complex. (2009) (0)
Editorial comment: diagnosis of focal brain lesions--old lessons retaught. (2003) (0)
Blood biomarkers for HIV infection with focus on neurologic complications—A review (2022) (0)
Alteration of tyrosine hydroxylase activity in PC12 cells infected with herpes simplex virus type 1 (2005) (0)
Are practice effects an important confounder of longitudinal studies of HIV-associated neurocognitive disorders? (2013) (0)
Kaposi's sarcoma and central nervous system disease: a real association or an artifact of the control group? (2000) (0)
Abstract 42. Metabolic alterations of HSV-1-infected neurons: studies using the PC12 cell as a model system (1985) (0)
Depression and Mood States and Correlations with Biomarkers of Central Nervous System Disease in Primary-HIV Infection (P01.262) (2012) (0)
Endothelial function and CNS measures in primary HIV infection pre-and post early ART (P2.314) (2015) (0)
Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection (2013) (0)
Pharmacokinetics (PK) of stavudine (d4T) in cerebrospinal fluid (CSF) of HIV infected subjects using sparse sampling (1999) (0)
HIV Brain Infection and Dementia (2001) (0)
CSF p-tau and Amyloid Beta 1-42 in HIV infection (2009) (0)
Viral infections of the nervous system. By Richard T. Johnson New York, Raven Press, 1982 433 pp, illustrated (1983) (0)
A new approach to cognitive impairment in people with HIV. (2022) (0)
Abstract 65. Diagnostic imaging of herpes simplex encephalitis (1985) (0)
Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection (2022) (0)
Pursuit EyeMovementDysfunction inHIV-1Seropositive Individuals (1991) (0)
Contents Vol. 41, 2013 (2013) (0)
Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus (2023) (0)
NEUROPATHOLOGY OF VARICELLA ZOSTER VIRUS(VZV) MYELITIS: 40 (1989) (0)
Reply to Seligman (2011) (0)
Impact of antiretroviral therapy on HIV-related brain injury. (2011) (0)
Neuroimmunology of CNS HIV Infection: A Narrative Review (2022) (0)
Overview of HIV CNS Infection (2016) (0)
No support for premature CNS aging in HIV when measured by cerebrospinal fluid hyperphosphorylated tau (p-tau) (2017) (0)
AIDS dementia complex (ADC) and HIV infection of the CNS: Pathophysiologically-based approach to treatment and evaluation (1997) (0)
45A A clinical events system with committee review for a large clinical trials network (1995) (0)
Progressive Increase in Cerebrospinal Fluid (CSF) Neopterin and Relation to Neuropsychological Performance during Primary HIV-1 Infection Prior to Antiretroviral Therapy (P06.189) (2013) (0)
The AIDS dementia complex as a model for other neurodegenerative diseases: a pathogenetic conceit (1994) (0)
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect (2013) (0)
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALITIS WITH INTRANUCLEAR PARTICLES RESEMBLING HERPESVIRUS: 62 (1979) (0)
ReviewCerebrospinal fluid neopterin : an informative biomarker of central nervous system immune activation in HIV-1 infection (2015) (0)
Longitudinal Characteristics Of Depression And Mood States Beginning In Primary Hiv Infection (2017) (0)
Neurocognitive Impairment of HIV Elite Controllers: Feature of Viral Suppression and Inflammation? (S53.004) (2016) (0)
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction (2023) (0)
Editorial comment: AIDS dementia complex in the current era. (2006) (0)
Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals (2018) (0)
Comprehensive Clinical Biofluid Investigation and Correlation of HIV Associated Subjects (2014) (0)
Correction: Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection (2022) (0)
therapy in primary HIV infection Cerebral metabolite changes prior to and after antiretroviral (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard William Price?

Richard William Price is affiliated with the following schools:

Richard William Price's Academic­Influence.com Rankings

Richard William Price's Degrees

Why Is Richard William Price Influential?

Richard William Price's Published Works

Published Works

What Schools Are Affiliated With Richard William Price?

Richard William Price's AcademicInfluence.com Rankings